{"id":"W2127385754","doi":"10.1016/s1470-2045(14)70030-0","title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; BC Cancer Agency","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Sorafenib; Open label; Renal cell carcinoma; Medicine; Oncology; Internal medicine; Second line treatment; Hepatocellular carcinoma; Clinical trial; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019243,0.002659433,0.004053774,0.0004802277,0.0005636187,0.001696412,0.001112174,0.002346589,0.00850352],"category_scores_gemma":[0.002401095,0.0008994743,0.003632124,0.0004791198,0.001528128,0.002017546,0.0005787122,0.004958347,0.001573071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001209227,"about_ca_system_score_gemma":0.001158929,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001335451,"about_ca_topic_score_gemma":0.002929201,"domain_scores_codex":[0.999244,0.0003709061,0.00004090237,0.0001377821,0.00005217074,0.000154294],"domain_scores_gemma":[0.9988432,0.0003792354,0.0002244548,0.00009812289,0.00006642899,0.0003885847],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9876293,0.002044199,0.0001997121,0.0004146505,0.0008909221,0.00002674028,0.00004003121,0.0003344367,0.0007669191,0.00009605258,0.0006069865,0.006950078],"study_design_scores_gemma":[0.9775279,0.02080747,0.0004222904,0.00002369189,0.0002824325,0.00002336644,0.00001858621,0.0003140643,0.0001196703,0.0001670108,0.000281639,0.00001178213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799304,0.006781318,0.001369561,0.001758857,0.001538933,0.003745101,0.001678527,0.0002213584,0.002975877],"genre_scores_gemma":[0.9853117,0.00296966,0.001324308,0.001361369,0.0005171134,0.003010519,0.001346845,0.00004545191,0.004113034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00850352,"threshold_uncertainty_score":0.02844715,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1290889388003442,"score_gpt":0.3833123518399601,"score_spread":0.2542234130396159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}